{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-252618","form_type":"8-K","ticker":"XOMA","cik":"0000791908","company_name":"XOMA Royalty Corp","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.029593+00:00","generated_at":"2026-05-30T04:07:16.531563+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"XOMA Q3: Revenue $7.2M, net loss $17.2M ($14M impairment); Twist 50% interest acquired","bullets":["Total income/revenue of $7.2M in Q3 2024 vs $0.8M in Q3 2023; cash receipts $9.9M.","Net loss of $17.2M vs $5.5M loss, driven by $14M non-cash impairment on Agenus royalty purchase agreement.","Acquired 50% economic interest in Twist Bioscience's 60+ partnered early-stage programs for $15M.","Cash and cash equivalents of $146.8M at Sept 30, 2024, down from $159.6M at Dec 31, 2023.","Zevra's MIPLYFFA (arimoclomol) received FDA approval for Niemann-Pick disease type C, adding commercial royalty."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-252618","json":"https://secwatch.observer/filing/0001193125-24-252618.json","markdown":"https://secwatch.observer/filing/0001193125-24-252618.md","text":"https://secwatch.observer/filing/0001193125-24-252618.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/791908/000119312524252618/0001193125-24-252618-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/791908/000119312524252618/d835519d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:07:16.531563+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}